Summary

The 7 major vasomotor symptoms markets reached a value of US$ 2.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.2% during 2024-2034.

The Vasomotor Symptoms Market has been comprehensively analyzed in IMARC's new report titled "Vasomotor Symptoms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast". Vasomotor symptoms are temperature dysfunctions that occur due to changes in gonadal hormones in females. These symptoms occur due to the constriction or dilation of blood vessels. These symptoms can also be referred to as menopausal symptoms, for which women seek treatment during menopause most often. At around the age of 40, estrogen and progesterone levels start to reduce in females. Therefore, as the females get older, a female may experience vasomotor symptoms. These hormonal fluctuations affect the mechanisms that control blood pressure and temperature control, and females may experience different symptoms. Vasomotor symptoms include hot flashes, night sweats, heart palpitations, and changes in blood pressure. Hormone therapy is the most effective treatment for vasomotor symptoms and other menopausal symptoms. Estrogens are known as potent neuromodulators of several neuronal circuits throughout the central nervous system. Changing estrogen levels during menopause may impact multiple components in maintaining temperature homeostasis. Similarly, for the drug discovery process, understanding the cause of thermoregulatory dysfunction and mechanisms involved in temperature regulation help specialists to introduce effective drugs.

The rising prevalence of menopausal and post-menopausal symptoms owing to the adoption of unhealthy eating habits and sedentary lifestyles is primarily driving the vasomotor symptoms market. In addition to this, the ongoing development of several treatment options that target the brain's thermostat to reduce the incidence of vasomotor symptoms, such as hot flashes, is acting as a significant growth-inducing factor. Furthermore, the emerging popularity of non-hormonal alternatives, such as selective serotonin reuptake inhibitors and selective serotonin-norepinephrine reuptake inhibitors, among patients with a history of breast cancer is also bolstering the market growth. Apart from this, the escalating demand for cognitive behavior therapy for treating complications associated with vasomotor symptoms, such as sleep disturbances and low-productivity levels in professional environments, is further creating a positive outlook for the market. This nonpharmacologic treatment aids in modifying dysfunctional emotions, behaviors, and thoughts that enhance personal coping strategies. Additionally, several governing bodies, along with non-governmental organizations (NGOs), are supporting various health education campaigns to address the stigma and associated silence pertaining to symptoms of menopause. This, in turn, is also propelling the adoption of drugs and medications for the treatment of vasomotor symptoms. Apart from this, the introduction of various innovative approaches for treating distressing vasomotor symptoms with the lowest effective dose in the shortest duration is expected to drive the vasomotor symptoms market in the coming years.

IMARC Group's new report "Vasomotor Symptoms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Vasomotor Symptoms market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Vasomotor Symptoms market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Vasomotor Symptoms across the seven major markets. According to the report the United States has the largest patient pool for Vasomotor Symptoms and also represents the largest market for Vasomotor Symptoms treatment. Furthermore, the current Vasomotor Symptoms treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Vasomotor Symptoms market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, Current and Future Epidemiology Scenario
Historical, Current and Future Performance of the Vasomotor Symptoms Market
Historical, Current and Future Performance of Various Therapeutic Categories in the Vasomotor Symptoms Market
Sales of Various Drugs Across the Vasomotor Symptoms Market
Reimbursement Scenario in the Vasomotor Symptoms Market
In-Market and Pipeline Drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Vasomotor Symptoms marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights

How has the Vasomotor Symptoms market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Vasomotor Symptoms market across the seven major markets in 2023 and how will it look like in 2034?
What is the growth rate of the Vasomotor Symptoms market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Vasomotor Symptoms market?

Epidemiology Insights

What is the size of the Vasomotor Symptoms patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Vasomotor Symptoms across the seven major markets?
What are the key factors driving the epidemiological trend of Vasomotor Symptoms?
What will be the growth rate of Vasomotor Symptoms patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed Vasomotor Symptoms drugs and what are their market performance?
What are the key pipeline Vasomotor Symptoms drugs and how are they expected to perform in the coming years?
How safe are the current marketed Vasomotor Symptoms drugs and what are their efficacies?
How safe are the late-stage pipeline Vasomotor Symptoms drugs and what are their efficacies?
What are the current treatment guidelines for Vasomotor Symptoms drugs across the seven major markets?
Who are the key companies in the Vasomotor Symptoms market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Vasomotor Symptoms market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Vasomotor Symptoms - Introduction
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence

5 Vasomotor Symptoms - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Vasomotor Symptoms - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)

8 Vasomotor Symptoms - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Vasomotor Symptoms Guidelines, Management and Treatment
8.2 Vasomotor Symptoms Treatment Algorithm

9 Vasomotor Symptoms - Unmet Needs

10 Vasomotor Symptoms - Key Endpoints of Treatment

11 Vasomotor Symptoms - Marketed Products
11.1 List of Vasomotor Symptoms Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Vasomotor Symptoms - Pipeline Drugs
12.1 List of Vasomotor Symptoms Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status

Kindly note that complete list of pipeline drugs has been provided in the report.

13. Vasomotor Symptoms - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Vasomotor Symptoms - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Vasomotor Symptoms - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Vasomotor Symptoms - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Vasomotor Symptoms - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Vasomotor Symptoms - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Vasomotor Symptoms - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Vasomotor Symptoms - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Vasomotor Symptoms - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Vasomotor Symptoms - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Vasomotor Symptoms - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Vasomotor Symptoms - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Vasomotor Symptoms - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Vasomotor Symptoms - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Vasomotor Symptoms - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Vasomotor Symptoms - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Vasomotor Symptoms - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Vasomotor Symptoms - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Vasomotor Symptoms - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Vasomotor Symptoms - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Vasomotor Symptoms - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Vasomotor Symptoms - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Vasomotor Symptoms - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Vasomotor Symptoms - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Vasomotor Symptoms - Access and Reimbursement Overview

15 Vasomotor Symptoms - Recent Events and Inputs From Key Opinion Leaders

16 Vasomotor Symptoms Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats

17 Appendix